Fig. 5

Reduction of AR expression increased chemosensitivity of glioma cells to TMZ in vivo. a U87-MG cells were inoculated subcutaneously into the flank of nude mice. Mice with appropriate size of tumors were divided randomly into four groups (n = 4) including vehicle-treated group, VPA-treated group (30 mg/day), TMZ-treated group (10 mg/kg/day) and combination of two. TMZ and VPA were administered by intraperitoneal injection once every 2 days for 20 days. b Photographs of xenograft tumors from each group were captured on day 21 after treatment. c AR expression in xenograft tumors in vehicle-treated and VPA-treated groups were analyzed by immunohistochemical staining with an antibody against AR (arrows indicate increased secretion). Scale bar = 100 μm. d AR knockdown enhanced response to TMZ treatment in vivo (n = 3)